U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H28O8
Molecular Weight 384.4216
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARTESUNATE

SMILES

C[C@]1([H])CC[C@@]2([H])[C@@]([H])(C)[C@]([H])(OC(=O)CCC(=O)O)O[C@@]3([H])[C@]42[C@@]1([H])CC[C@](C)(O3)OO4

InChI

InChIKey=FIHJKUPKCHIPAT-AHIGJZGOSA-N
InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H28O8
Molecular Weight 384.4216
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

treatment of falciparum malaria since 1990. It is a potent antimalarial drug that can reduce parasitaemia by 90% within 24 h of administration. Sodium artesunate was first isolated in China, it is a water soluble antimalaria used clinically in China.

CNS Activity

Curator's Comment:: Active metabolite of artesunate was detected in CSF after intravenous administration of artesunate.

Originator

Sources: http://adisinsight.springer.com/drugs/800023198https://www.ncbi.nlm.nih.gov/pubmed/8891104Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (1982), 2, (2), 99-103.
Curator's Comment:: Indicated originators are originators of Dihydroartemisinin/piperaquine formulation. Originator of Dihydroartemisinin is unknown.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Sodium artesunate

Approved Use

Plasmodium falciparum malaria
Curative
Eurartesim

Approved Use

Eurartesim tablets (piperaquine tetraphosphate in combination with dihydroartemisinin) are indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants aged ≥6 months and weighing ≥5kg.

Launch Date

1319587200000
Curative

Approved Use

Although not FDA-approved for use in the United States, artesunate is used as the treatment of choice for severe malaria by the World Health Organization (WHO) over quinidine.
Curative
Primary
Primary
Primary
Primary
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
3.3 μg/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.5 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.7 μg × h/mL
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.3 h
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTENIMOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7%
2.4 mg/kg multiple, intravenous
dose: 2.4 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ARTESUNATE unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Other AEs: Anemia, Transaminases increased...
Other AEs:
Anemia (65%)
Transaminases increased (27%)
Thrombocytopenia (18%)
Hyperbilirubinemia (14%)
Acute renal failure (10%)
Leukocytosis (10%)
Acute respiratory distress syndrome (8%)
Lymphopenia (7%)
Neutropenia (5%)
Disseminated intravascular coagulation (3%)
Creatinine increased (3%)
Pneumonia (3%)
Pulmonary edema (3%)
Diarrhea (3%)
Sources:
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (grade 1, 45%)
Dizziness (grade 1, 52%)
Vomiting (grade 1, 26%)
Convulsions (grade 1, 3%)
Bradycardia (grade 1, 23%)
Sources:
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Other AEs: Acute renal failure, Hemoglobinuria...
Other AEs:
Acute renal failure (8.9%)
Hemoglobinuria (6.7%)
Jaundice (2.3%)
Sources:
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Nausea, Vomiting...
Dose limiting toxicities:
Nausea (grade 3, 1 patient)
Vomiting (grade 3, 1 patient)
ALT increased (grade 3-4, 1 patient)
Neutropenic infection (grade 3-4, 1 patient)
Sources:
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Hypersensitivity reaction...
Dose limiting toxicities:
Hypersensitivity reaction (grade 3, 1 patient)
Sources:
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
DLT: Neutropenic fever...
Dose limiting toxicities:
Neutropenic fever (grade 3, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acute renal failure 10%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Leukocytosis 10%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Hyperbilirubinemia 14%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Thrombocytopenia 18%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Transaminases increased 27%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Creatinine increased 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Diarrhea 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Disseminated intravascular coagulation 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Pneumonia 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Pulmonary edema 3%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Neutropenia 5%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Anemia 65%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Lymphopenia 7%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Acute respiratory distress syndrome 8%
2.4 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 1-72 years
Health Status: unhealthy
Age Group: 1-72 years
Sex: M+F
Sources:
Bradycardia grade 1, 23%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Vomiting grade 1, 26%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Convulsions grade 1, 3%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Nausea grade 1, 45%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Dizziness grade 1, 52%
100 mg 1 times / day multiple, oral
Studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 15-35 years
Health Status: unhealthy
Age Group: 15-35 years
Sex: M
Sources:
Jaundice 2.3%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Hemoglobinuria 6.7%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Acute renal failure 8.9%
2.4 mg/kg 1 times / day multiple, intravenous|oral
Recommended
Dose: 2.4 mg/kg, 1 times / day
Route: intravenous|oral
Route: multiple
Dose: 2.4 mg/kg, 1 times / day
Sources:
unhealthy, 2-87 years
Nausea grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Vomiting grade 3, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
ALT increased grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Neutropenic infection grade 3-4, 1 patient
DLT
25 mg/kg 2 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 25 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 25 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Hypersensitivity reaction grade 3, 1 patient
DLT
18 mg/kg 2 times / 3 weeks multiple, intravenous
MTD
Dose: 18 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 18 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Neutropenic fever grade 3, 1 patient
DLT
12 mg/kg 2 times / 3 weeks multiple, intravenous
Studied dose
Dose: 12 mg/kg, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 12 mg/kg, 2 times / 3 weeks
Sources:
unhealthy, 58 years
Health Status: unhealthy
Age Group: 58 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
weak [IC50 32.3 uM]
weak [IC50 75.4 uM]
yes
yes
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.
2003 Jan
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.
2005 Feb-Apr
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
2005 Jan-Feb
Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa.
2007 Dec 21
Treatment of experimental nephrotic syndrome with artesunate.
2007 Jul-Aug
Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand.
2008 Nov 6
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Oral route is possible: One group of 45 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 4 days for a total of 1200 mg (group I: 5-day treatment). A second group of 46 patients received 400 mg of Sodium artesunate on the first day of treatment and then 200 mg daily for 6 days for a total of 1600 mg (group II: 7-day treatment). 5- or 7-day regimens of sodium artesunate with a total dose of 1200-1600 mg are effective and safe in treating falciparum malaria acquired in Thailand.
Eurartesim (piperaquine tetraphosphate (PQP)/
Route of Administration: Oral
dihydroartemisinin at micromolar dose levels exhibits a dose- and time-dependent cytotoxicity in ovarian cancer cell lines.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:32:58 UTC 2021
Edited
by admin
on Sat Jun 26 13:32:58 UTC 2021
Record UNII
60W3249T9M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARTESUNATE
DASH   HSDB   INN   MART.   MI   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
ARTESUNATE [USP-RS]
Common Name English
4-OXO-4-(3R,5AS,6R,8AS,9R,10S,12R,12AR)-3,6,9-TRIMETHYLDECAHYDRO-3,12-EPOXYPYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL HYDROGEN BUTANEDIOATE
Common Name English
LJPC-0118
Code English
BUTANEDIOIC ACID, MONO(DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL) ESTER, (3R-(3.ALPHA.,5A.BETA.,6.BETA.,8A.BETA.,9.ALPHA.,10.BETA.,12.BETA.,12AR*))-
Systematic Name English
ARTESUNATE [WHO-IP]
Common Name English
ZYSUNATE
Brand Name English
ARTESUNATE [USAN]
Common Name English
SAPHNATE
Common Name English
ARTESUNATE [HSDB]
Common Name English
ARTESUNATE [WHO-DD]
Common Name English
ARTESUNATE [VANDF]
Common Name English
.ALPHA.-ARTESUNIC ACID
Common Name English
ARTESUNATE [MI]
Common Name English
ARTESUNATE [MART.]
Common Name English
ARTESUNATUM [WHO-IP LATIN]
Common Name English
NSC-712571
Code English
DIHYDROQINGHAOSU HEMISUCCINATE
Common Name English
3R,5AS,6R,8AS,9R,10S,12R,12AR)-3,6,9-TRIMETHYLDECAHYDRO-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL HYDROGEN BUTANEDIOATE
Systematic Name English
DIHYDROARTEMISININE-12.ALPHA.-SUCCINATE
Common Name English
BUTANEDIOIC ACID, MONO((3R,5AS,6R,8AS,9R,10S,12R,12AR)-DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL) ESTER
Common Name English
QINGHAOZHI
Common Name English
ARTESUNATE [INN]
Common Name English
ARTESUNIC ACID
Common Name English
PLASMOTRIN
Brand Name English
(3R,5AS,6R,8AS,9R,10S,12R,12AR)-DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL, HYDROGEN SUCCINATE
Systematic Name English
ARSUMAX
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 651218
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
FDA ORPHAN DRUG 598517
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
FDA ORPHAN DRUG 221206
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ATC P01BE03
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
FDA ORPHAN DRUG 693719
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1 (ART/AMO)
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ATC P01BF03
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ATC P01BF02
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ATC P01BF04
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
WHO-ATC P01BF06
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
EU-Orphan Drug EU/3/15/1521
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
FDA ORPHAN DRUG 125599
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
NCI_THESAURUS C277
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
Code System Code Type Description
DRUG CENTRAL
247
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
LACTMED
Artesunate
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
CAS
88495-63-0
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL361497
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
INN
6459
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
RXCUI
18346
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY RxNorm
EPA CompTox
88495-63-0
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
DRUG BANK
DB09274
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
MERCK INDEX
M2078
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY Merck Index
FDA UNII
60W3249T9M
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
PUBCHEM
6917864
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
NCI_THESAURUS
C73005
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
HSDB
7458
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ARTESUNATE
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY Description: A fine, white crystalline powder. Solubility: Very slightly soluble in water; very soluble in dichloromethane R; freely soluble in ethanol (~750 g/l) TS and acetone R. Category: Antimalarial. Storage: Artesunate should be kept in a well-closed container or, if sterile, in a hermetically closed container. It should be protected from light. Labelling: The label states where applicable:? that the substance is free from bacterial endotoxins;? that the substance is sterile. Definition: Artesunate contains not less than 96.0% and not more than 102.0% of artesunate (C19H28O8) using Assay method A, and not less than 98.0% and not more than 102.0% of artesunate (C19H28O8) using Assay method B, both calculated with reference to the anhydrous substance.
MESH
C039726
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
USP_CATALOG
1042850
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY USP-RS
EVMPD
SUB05576MIG
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
WIKIPEDIA
ARTESUNATE
Created by admin on Sat Jun 26 13:32:59 UTC 2021 , Edited by admin on Sat Jun 26 13:32:59 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
WEAK
IC50
TARGET ORGANISM->INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
WEAK
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PRODRUG
ratio of alpha to beta DIHYDROARTEMISININ is 3.5
PLASMA
Related Record Type Details
IMPURITY -> PARENT
In the chromatogram obtained with solution (1): the area of any peak corresponding to impurity B (artemisinin) is not greater than 0.5 times the area of the principal peak obtained with solution (4) (0.5%).
IMPURITY -> PARENT
In the chromatogram obtained with solution (1): the area of any peak corresponding to impurity C, when multiplied by a correction factor of 0.07, is not greater than 0.2 times the area of the principal peak obtained with solution (4) (0.2%) the sum of the corrected area of any peak corresponding to impurity C and the areas of all other peaks, other than the principal peak, is not greater than twice the area of the principal peak obtained with solution (4) (2.0%).
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

IN PATIENTS WITH SEVERE MALARIA

Biological Half-life PHARMACOKINETIC IN PATIENTS WITH SEVERE MALARIA

INTRAVENOUS ADMINISTRATION